Skip to main content
. 2016 Jul 5;106(1):18–27. doi: 10.1007/s00392-016-1019-4

Table 3.

Primary, secondary, and clinical outcome measures at follow-up

Outcome measures N = 39 patients (47 lesions)
Primary LLL (mm) −0.13 ± 0.44
Secondary NLG (mm) 1.1 ± 0.53
Clinical TLR at 6-month f/u 1/2a
MACE at 6-month f/u 2/3a
MACE at 1-year f/u 2/3a

Results are shown as per-protocol analysis

LLL late lumen loss, NLG net luminal gain, TLR target lesion revascularization, MACE major adverse cardiovascular events, f/u follow-up

aIntention-to-treat analysis (N = 54 lesions in 46 patients)